Chen, Shuna
Han, Chao
Shi, Zihan
Guan, Xin
Cheng, Liyuan
Wang, Liang
Zou, Wei
Liu, Jing https://orcid.org/0000-0002-0493-296X
Funding for this research was provided by:
Dalian Science and Technology Talent Innovation Support Policy Implementation Plan High-level Talent Team (2022RG18)
Liaoning Province Science and Technology Plan Orientation Project ([2021]49)
Dalian high-level talent innovation support plan (2021RQ028)
Liaoning Province Natural Science Foundation project (2022-BS-238)
Article History
Received: 24 September 2024
Accepted: 11 February 2025
First Online: 12 March 2025
Declarations
:
: This study was conducted at the Stem Cell Clinical Research Center of the First Affiliated Hospital of Dalian Medical University. The study, titled "Clinical Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Acute Ischemic Stroke" (No. YJ-GXB-2022-01, January 16, 2022), received ethical approval from the Ethics Committee of the First Affiliated Hospital of Dalian Medical University. The approval encompassed the isolation and preparation of human umbilical cord mesenchymal stem cells, the recruitment of patients with acute ischemic stroke, and the collection of their biological samples for research purposes. Written informed consent was obtained from all patients or their legally authorized representatives. The animal studies were approved by the Ethics Committee of the Animal Experiment Center of Dalian Medical University and conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The approved project was titled "Investigation of the Effects of Stem Cells and Engineered Vesicles on Neurological Repair in Ischemic Stroke" (No. AEE23127, February 28, 2023). In addition, this work has been reported in line with the ARRIVE guidelines 2.0. There were no ethical conflicts associated with this manuscript.
: Not applicable.
: The authors declare that they have not use AI-generated work in this manuscript" in this section.
: The authors declare that they have no competing interests.